Pauline Faucher

Dr. Pauline Faucher

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 June 2021 in Nutrients
Verified
Journal Article
Open access
PDF file
DBDorothée Bedock
Dorothée Bedock
JCJulie Couffignal
Julie Couffignal
PLPierre Bel Lassen
Pierre Bel Lassen
LSLeila Soares
Leila Soares
AMAlexis Mathian
Alexis Mathian
PFPauline Faucher
Pauline Faucher
Background & Aims: SARS-CoV2 infection is associated with an increased risk of malnutrition. Although there are numerous screening and nutritional management protocols for malnutrition, only few studies have reported nutritional evolution after COVID-19. The objectives of this study were to describe the evolution of nutritional parameters between admission and 30 days after hospital discharge, and to determine predictive factors of poor nutritional outcome after recovery in adult COVID-19 patients. Methods: In this observational longitudinal study, we report findings after discharge in 91 out of 114 patients initially admitted for COVID-19 who received early nutritional management. Nutritional status was defined using GLIM criteria and compared between admission and day 30 after discharge. Baseline predictors of nutritional status at day 30 were assessed using logistic regression. Results: Thirty days after discharge, 28.6% of patients hospitalized for COVID-19 were malnourished, compared to 42.3% at admission. Half of malnourished patients (53%) at admission recovered a normal nutritional status after discharge. Weight trajectories were heterogeneous and differed if patients had been transferred to an intensive care unit (ICU) during hospitalization (p = 0.025). High oxygen requirement during hospitalization (invasive ventilation p = 0.016 (OR 8.3 [1.6–61.2]) and/or oxygen therapy over 5 L/min p = 0.021 (OR 3.2 [1.2–8.9]) were strong predictors of malnutrition one month after discharge. Conclusions: With early nutritional management, most patients hospitalized for COVID-19 improved nutritional parameters after discharge. These findings emphasize the importance of nutritional care in COVID-19 patients hospitalized in medicine departments, especially in those transferred from ICU.

6 May 2022 in Obesity Surgery
Verified
Journal Article
Closed access
PDF file
PFPauline Faucher
Pauline Faucher
CCClaire Carette
Claire Carette
AJAnne-Sophie Jannot
Anne-Sophie Jannot
BGBlandine Gatta-Cherifi
Blandine Gatta-Cherifi
ASAlexis Van Straaten
Alexis Van Straaten
SCSébastien Czernichow
Sébastien Czernichow

25 June 2019 in Obesity Surgery
Verified
Journal Article
Closed access
PDF file
PFPauline Faucher
Pauline Faucher
JAJudith Aron-Wisnewsky
Judith Aron-Wisnewsky
CCCécile Ciangura
Cécile Ciangura
LGLaurent Genser
Laurent Genser
ATAdriana Torcivia
Adriana Torcivia
JOJean-Michel Oppert
Jean-Michel Oppert

28 October 2025 in Diabetes, Obesity and Metabolism
Verified
Journal Article
Open access
FLFlora Lambert
Flora Lambert
EGEmilie Guillon
Emilie Guillon
BGBlandine Gatta‐Cherifi
Blandine Gatta‐Cherifi
HSHedi Soula
Hedi Soula
CPChristine Poitou
Christine Poitou
PFPauline Faucher
Pauline Faucher
Aims: Acquired hypothalamic obesity (aHO) following craniopharyngioma (CP) is a challenging condition with limited therapeutic options. This study aimed to assess the real‐world effectiveness and safety of GLP‐1 RAs in this population. Materials and Methods: CranioGLP1 is a retrospective multicentre study including 116 adults with aHO treated with one or more GLP‐1 RAs across 16 French obesity centres. Demographic, clinical, and therapeutic data were collected from medical records. Weight outcomes, adverse events, and predictors of response were analysed. Results: Patients had a mean age of 44.4 ± 13.5 years and a mean BMI of 40.1 ± 8.6 kg/m 2 , 42% had type 2 diabetes. Over a mean follow‐up of 44 months, mean weight loss was −4.6% (±12.5), with high interindividual variability; 51% achieved ≥5% weight loss, and 28% ≥10%. Semaglutide (mean dose 1.2 mg/week) was associated with the greatest reduction (−6.8%), particularly in patients without diabetes (−8.5% ± 12.3 vs. −3.9% ± 10.0 in those with diabetes; p = 0.032). Endocrine adverse events occurred in 12% and 10% of patients with adrenal or vasopressin deficiency decompensation, respectively, with 8% requiring hospitalisation. Gastrointestinal intolerance led to treatment discontinuation in 13% of cases. Conclusions: GLP‐1 RAs at submaximal doses induce moderate, yet clinically meaningful weight loss in adults with aHO, with semaglutide showing the highest efficacy. Given the non‐negligible risk of hormonal decompensation, specific endocrine monitoring is essential.

1 December 2014 in Nutrition Clinique et Métabolisme
Verified
Journal Article
Closed access
CCCécile Ciangura
Cécile Ciangura
PFPauline Faucher
Pauline Faucher
JOJean-Michel Oppert
Jean-Michel Oppert

1 December 2016 in Soins
Verified
Journal Article
Closed access
PFPauline Faucher
Pauline Faucher
CPChristine Poitou
Christine Poitou